Go 6983 and PKC Hyperactivity in Striatal Circuits

2026-08-27

Go 6983, a pan-PKC inhibitor, provides a reversible way to test whether PKC hyperactivity links NLGN1 loss to repetitive behavior. This article translates striatal circuit findings into rigorous assay design while defining the limits of cross-domain interpretation.

2-Deoxy-D-glucose: Mechanism, Evidence, and Workflow

2026-08-26

2-Deoxy-D-glucose (2-DG) is a glucose analog used to study glycolysis inhibition, ATP depletion, and metabolic stress. Product benchmarks include concentration-dependent cytotoxicity in KIT-positive GIST models, antiviral activity against PEDV in Vero cells, and formulation guidance for reproducible experiments.

Nullscript in Placental Stress Assay Design

2026-08-26

Nullscript is a histone deacetylase inhibitor with a distinctive transcriptional inactivity profile. This article examines how it could serve as a hypothesis-testing perturbation in placental nanoplastic research without overstating evidence from cardiac ischemia/reperfusion models.

PKM2 inhibitor (compound 3k) Experimental Workflows

2026-08-25

PKM2 inhibitor (compound 3k) connects glycolysis-focused cancer assays with mechanistic immunometabolism studies. Its reported enzyme, cellular, and xenograft activity supports a practical workflow for testing aerobic glycolysis disruption, tumor cell selectivity, and PKM2-dependent phenotypes.

CaP-Pickering Emulsion for mRNA Cancer Vaccines

2026-08-25

The reference study engineers a calcium phosphate nanoparticle-stabilized water-in-oil-in-water Pickering emulsion to deliver mRNA while coordinating dendritic-cell and natural-killer-cell activation. Its results in E.G7 and B16-OVA tumor models suggest that carrier design can improve both cytosolic expression and antitumor immune engagement beyond an expression-only delivery strategy.

Protease Inhibitor Cocktail Workflow Guide

2026-08-24

Learn how an EDTA-free inhibitor blend protects fragile proteins for Western blotting, co-immunoprecipitation, phosphorylation analysis, and enzyme assays. This practical guide combines a cold-chain workflow, application-specific controls, and troubleshooting with insights from a recent atopic dermatitis hydrogel study.

CB-839 and the Metabolic Logic of MYCN Neuroblastoma

2026-08-24

CB-839 (Telaglenastat) provides a selective, reversible way to test whether GLS1-dependent glutaminolysis is a functional bottleneck downstream of PRMT5-driven splicing stress in MYCN-amplified neuroblastoma. This thought-leadership perspective connects mechanistic evidence with practical assay design and translational decision-making.

Eclipta–Hordeum Extract Delays Puberty in Rats

2026-08-23

A 2025 study tested an Eclipta prostrata–Hordeum vulgare extract complex in two rat models of precocious puberty induced by Danazol or a high-fat diet. The extract delayed vaginal opening, reduced ovarian maturation, and attenuated hypothalamic GnRH mRNA elevation without altering body weight, supporting further investigation of central HPG-axis modulation rather than direct clinical efficacy.

Spiroplasma Entry into Drosophila S2 Cells

2026-08-22

Dual Metabolic Reprogramming in TNBC Ferroptosis

2026-08-22

The reference study develops an iron-containing metal–polyphenol nanoplatform that combines DHODH and GPX4 suppression with DGAT1-directed lipid remodeling to overcome ferroptosis resistance in triple-negative breast cancer. Its central contribution is the identification of BQR-induced lipid-droplet accumulation as a countervailing mechanism and the validation of a coordinated metabolic intervention in cellular and animal models.

CB-839 Workflows for Glutamine Metabolism

2026-08-21

CB-839, also called Telaglenastat, gives researchers a selective and reversible way to test GLS1 dependence across viability, metabolite, autophagy, and combination experiments. This workflow connects direct glutaminolysis inhibition with the PRMT5-linked metabolic vulnerability reported in MYCN-amplified neuroblastoma.

BI 2536 Workflows for PLK1 Inhibition

2026-08-20

BI 2536 provides a selective way to connect PLK1 activity with mitotic arrest, checkpoint control, and apoptosis in cancer models. This guide translates its biochemical profile and a mechanistic study of p31comet into practical cell-based, extract-based, and tumor xenograft workflows.

Go 6983 Workflows for PKC Signaling Research

2026-08-20

Go 6983 is a practical pan-PKC inhibitor for separating PKC-dependent signaling from downstream changes in cancer, EMT, and neuronal assays. This workflow-focused guide covers concentration planning, controls, assay selection, and the limits of translating PKC findings between tumor and striatal models.

Chromatin Programs of Perinatal Cardiomyocyte Transition

2026-08-19

The reference study maps how chromatin accessibility, long-range regulatory interactions, and gene expression change as cardiomyocytes transition from fetal to neonatal states. Its identification of MEF2- and AP1-centered regulatory programs provides a framework for improving cardiomyocyte maturation and interpreting epigenetic interventions in cardiac research.

PKM2 inhibitor (compound 3k) Workflow

2026-08-19

PKM2 inhibitor (compound 3k) connects cancer-cell metabolic studies with mechanistic immunometabolism assays, enabling a practical comparison of glycolysis, viability, autophagy, and inflammatory phenotypes. This workflow highlights its value as a pyruvate kinase M2 inhibitor while clarifying why dose selection and cell-context controls are essential.